CROs offering Discovery Research with Biologics (Monoclonal Antibodies)
24 published
24 published CROs match Discovery Research and Biologics (Monoclonal Antibodies).
Locations in this set include United States, China, United Kingdom, Australia, Canada, and France.
Capabilities that show up most often in this set: Preclinical In Vivo Studies, In Vitro Pharmacology, Target Identification & Validation, Translational Research, and In Vitro ADME / DMPK.
Matching companies
Sygnature DiscoveryIntegrated drug discovery CRO covering target identification through lead optimization, with computational design, structural biology, medicinal chemistry and DMPK support. Serves biotech and pharma clients across the US, Canada, UK and Europe.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
TRiCBIOTRiCBIO provides human organoid research services for efficacy, safety, mechanism and immune-context studies using PDO 2.0 and ALI platforms, supporting biopharma and CRO teams in candidate evaluation and translational research.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/discovery-research/biologics-monoclonal-antibodies.md